Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Alto Neuroscience Inc (ANRO)
NYSEHealth CareBiotechnologySnapshot 2026-11-04
$21.87-6.14%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ANRO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash balance to support operations through 2029 | Alto Neuroscience is focused on maintaining cash to fund operations through 2029. | Intact | Cash balance falls below levels needed to fund operations through 2029 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development company, not an established earnings compounder, because it is loss-making and its results are weak. The thesis is in a watch state: management is progressing its main trial plans and reports cash runway through 2029–2030, but confidence in the overall evidence is low.
The snapshot gives no usable valuation comparison or clear account of market expectations, so whether ANRO is cheap, fair, or expensive versus peers cannot be assessed. It reports low fragility in priced-in signals, while the recent thesis response has been muted; neither establishes how much clinical progress the market already assumes.
Near term, ANRO remains loss-making, with recent financial performance rated weak and an elevated risk of a miss at the next report. An August earnings beat is a positive event, but it does not change the broader weak-performance assessment. Over the multi-year view, ALTO-207 Phase 2b enrollment is reported on track, with topline data expected in the second half of 2027 and Phase 3 trials planned for 2027; reported cash is expected to fund operations through 2029–2030.
The thesis depends on ALTO-207 trial progress, data quality, and whether the planned studies produce useful results; patient-screening measures are new, and their delivery is not yet assessable. A guidance cut or further weakening in the jobs trend could add pressure, while stronger results and guidance from healthcare bellwethers could support sector sentiment.
For the next 1–3 years, ANRO’s thesis combines a funded development runway and stated clinical progress with weak financial performance, loss-making operations, and substantial clinical and near-term reporting risk. The evidence supports continued uncertainty rather than a clear change in thesis state. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating losses are managed while advancing clinical programs. |
| Intact |
| Significant clinical trial failures or delays |
Qualitative: No trial failures reported; $100M raised News confirms $100M stock offering and expanded Phase 2b/3 plans for ALTO-207, with no reported trial failures or delays. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating losses and cash burn | Operating losses are managed while advancing clinical programs. | Intact | Operating losses increase materially beyond -$27.1M | Operating income: $-29.129M FY2026-Q2; GAAP. Published target: Operating losses do not worsen beyond -$27.1M next quarter. Target period is not explicitly aligned with this observation. Aug 12, 2026-29,129,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.21 → $-3.01 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.21 | Unavailable | 8 / 0 |
| 2026-07-25 | $-3.21 | Unavailable | 8 / 0 |
| 2026-07-26 | $-3.21 | Unavailable | 8 / 0 |
| 2026-07-27 | $-3.21 | Unavailable | 8 / 0 |
| 2026-07-28 | $-3.21 | Unavailable | 8 / 0 |
| 2026-07-29 | $-3.43 | $0 | 6 / 10 |
| 2026-07-30 | $-3.43 | $0 | 6 / 10 |
| 2026-07-31 | $-3.43 | $0 | 6 / 10 |
| 2026-08-01 | $-3.43 | $0 | 6 / 10 |
| 2026-08-02 | $-3.43 | $0 | 6 / 10 |
| 2026-08-03 | $-3.43 | $0 | 6 / 10 |
| 2026-08-04 | $-3.43 | $0 | 6 / 10 |
| 2026-08-05 | $-3.43 | $0 | 6 / 10 |
| 2026-08-06 | $-3.43 | $0 | 6 / 10 |
| 2026-08-07 | $-3.29 | Unavailable | 7 / 0 |
| 2026-08-08 | $-3.43 | $0 | 6 / 10 |
| 2026-08-09 | $-3.43 | $0 | 6 / 10 |
| 2026-08-10 | $-3.43 | $0 | 6 / 10 |
| 2026-08-11 | $-3.29 | Unavailable | 7 / 0 |
| 2026-08-12 | $-3.43 | $0 | 6 / 10 |
| 2026-08-13 | $-3.43 | $0 | 6 / 10 |
| 2026-08-14 | $-3.29 | Unavailable | 7 / 0 |
| 2026-08-15 | $-3.29 | Unavailable | 8 / 0 |
| 2026-08-16 | $-3.29 | Unavailable | 8 / 0 |
| 2026-08-17 | $-3.29 | Unavailable | 8 / 0 |
| 2026-08-18 | $-3.29 | Unavailable | 8 / 0 |
| 2026-08-19 | $-3.29 | Unavailable | 8 / 0 |
| 2026-08-20 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-21 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-22 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-23 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-24 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-25 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-26 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-27 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-28 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-29 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-30 | $-3.07 | Unavailable | 8 / 0 |
| 2026-08-31 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-01 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-02 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-03 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-04 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-05 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-06 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-07 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-08 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-09 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-10 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-11 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-12 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-13 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-14 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-15 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-16 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-17 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-18 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-19 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-20 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-21 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-22 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-23 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-24 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-25 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-26 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-27 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-28 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-29 | $-3.07 | Unavailable | 8 / 0 |
| 2026-09-30 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-01 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-02 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-03 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-04 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-05 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-06 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-07 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-08 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-09 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-10 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-11 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-12 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-13 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-14 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-15 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-16 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-17 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-18 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-19 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-20 | $-3.07 | Unavailable | 8 / 0 |
| 2026-10-21 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-22 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-23 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-24 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-25 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-26 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-27 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-28 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-29 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-30 | $-3.01 | Unavailable | 8 / 0 |
| 2026-10-31 | $-3.01 | Unavailable | 8 / 0 |
| 2026-11-01 | $-3.01 | Unavailable | 8 / 0 |
| 2026-11-02 | $-3.01 | Unavailable | 8 / 0 |
| 2026-11-03 | $-3.01 | Unavailable | 8 / 0 |
| 2026-11-04 | $-3.01 | Unavailable | 8 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.